Fatigue and cognitive symptoms in patients with diabetes: Relationship with disease phenotype and insulin treatment

Psychoneuroendocrinology

Volumn 37, Issue 9, 2012, Pages 1468-1478

  Lasselin, Julie ^a,b   Layé, Sophie ^a,b   Barreau, Jean Baptiste ^a,b   Rivet, Alice ^a,b   Dulucq, Marie Josée ^a,b   Gin, Henri ^c   Capuron, Lucile ^a,b  

^a NutriNeuro Bordeaux University   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Adiposity; Cognition; Complications; Diabetes; Disease phenotype; Fatigue; Glycated hemoglobin; Insulin treatment; Symptoms

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; BODY MASS; CAMBRIDGE NEUROPSYCHOLOGICAL AUTOMATED BATTERY; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FATIGUE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; MULTIDIMENSIONAL FATIGUE INVENTORY; NEUROPSYCHOLOGICAL TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PATTERN RECOGNITION; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUESTIONNAIRE; RESPONSE TIME; SPATIAL DISCRIMINATION; TASK PERFORMANCE; TREATMENT DURATION;

ADULT; AGED; BLOOD GLUCOSE; CHOICE BEHAVIOR; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FATIGUE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REACTION TIME;

EID: 84864766424     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.01.016     Document Type: Article

References (59)

1. Alexandraki K.I., Piperi C., Ziakas P.D., Apostolopoulos N.V., Makrilakis K., Syriou V. Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation. J. Clin. Immunol. 2008, 28:314-321.
2. Benedict C., Hallschmid M., Schmitz K., Schultes B., Ratter F., Fehm H.L., Born J., Kern W. Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 2007, 32:239-243.
3. Bohringer A., Schwabe L., Richter S., Schachinger H. Intranasal insulin attenuates the hypothalamic-pituitary-adrenal axis response to psychosocial stress. Psychoneuroendocrinology 2008, 33:1394-1400.
4. Bower J.E., Ganz P.A., Tao M.L., Hu W., Belin T.R., Sepah S., Cole S., Aziz N. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin. Cancer Res. 2009, 15:5534-5540.
5. Brands A.M., Biessels G.J., de Haan E.H., Kappelle L.J., Kessels R.P. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 2005, 28:726-735.
6. Brands A.M., Kessels R.P., Hoogma R.P., Henselmans J.M., van der Beek Boter J.W., Kappelle L.J., de Haan E.H., Biessels G.J. Cognitive performance, psychological well-being, and brain magnetic resonance imaging in older patients with type 1 diabetes. Diabetes 2006, 55:1800-1806.
7. Brismar T., Maurex L., Cooray G., Juntti-Berggren L., Lindström P., Ekberg K., Adner N., Andersson S. Predictors of cognitive impairment in type 1 diabetes. Psychoneuroendocrinology 2007, 32:1041-1051.
8. Capuron L., Ravaud A., Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-α treatments in cancer patients. Psychosom. Med. 2001, 63:376-386.
9. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
10. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 2004, 56:819-824.
11. Capuron L., Pagnoni G., Demetrashvili M.F., Lawson D.H., Fornwalt F.B., Woolwine B., Berns G.S., Nemeroff C.B., Miller A.H. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007, 32:2384-2392.
12. Chasens E.R., Olshansky E. Daytime sleepiness, diabetes and psychological well-being. Issues Ment. Health Nurs. 2008, 29:1134-1150.
13. Craft S., Watson G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004, 3:169-178.
14. Dantzer R. Cytokine-induced sickness behavior: where do we stand?. Brain Behav. Immun. 2001, 15:7-24.
15. Drivsholm T., de Fine Olivarius N., Nielsen A.B., Siersma V. Symptoms, signs and complications in newly diagnosed type 2 diabetic patients, and their relationship to glycaemia, blood pressure and weight. Diabetologia 2005, 48:210-214.
16. Dulloo A.G., Jacquet J., Solinas G., Montani J.P., Schutz Y. Body composition phenotypes in pathways to obesity and the metabolic syndrome. Int. J. Obes. (Lond.) 2010, 34(Suppl. 2):S4-S17.
17. Elias P.K., Elias M.F., D'Agostino R.B., Cupples L.A., Wilson P.W., Silbershatz H., Wolf P.A. NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 1997, 20:1388-1395.
18. Feil D.G., Pearman A., Victor T., Harwood D., Weinreb J., Kahle K., Unützer J. The role of cognitive impairment and caregiver support in diabetes management of older outpatients. Int. J. Psychiatry Med. 2009, 39:199-214.
19. Figlewicz D.P., Szot P., Israel P.A., Payne C., Dorsa D.M. Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res. 1993, 602:161-164.
20. Figlewicz D.P., Szot P., Chavez M., Woods S.C., Veith R.C. Intraventricular insulin increases dopamine transporter mRNA in rat VTA/substantia nigra. Brain Res. 1994, 644:331-334.
21. Fritschi C., Quinn L. Fatigue in patients with diabetes: a review. J. Psychosom. Res. 2010, 69:33-41.
22. Fruehwald-Schultes B., Kern W., Born J., Fehm H.L., Peters A. Hyperinsulinemia causes activation of the hypothalamus-pituitary-adrenal axis in humans. Int. J. Obes. Relat. Metab. Disord. 2001, 25(Suppl. 1):S38-S40.
23. Gin H., Rigalleau V., Perlemoine C. Insulin therapy and body weight, body composition and muscular strength in patients with type 2 diabetes mellitus. J. Nutr. Metab. 2010, pii: 340570.
24. Gotoh M., Li C., Yatoh M., Okabayashi N., Habu S., Hirooka Y. Hypothalamic monoamine metabolism is different between the diabetic GK (Goto-Kakizaki) rats and streptozotocin-induced diabetic rats. Brain Res. 2006, 1073-1074:497-501.
25. Hassing L.B., Hofer S.M., Nilsson S.E., Berg S., Pedersen N.L., McClearn G., Johansson B. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 2004, 33:355-361.
26. Kern W., Peters A., Fruehwald-Schultes B., Deininger E., Born J., Fehm H.L. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 2001, 74:270-280.
27. Kyrou I., Tsigos C. Stress hormones: physiological stress and regulation of metabolism. Curr. Opin. Pharmacol. 2009, 9:787-793.
28. Lin J.M., Brimmer D.J., Maloney E.M., Nyarko E., Belue R., Reeves W.C. Further validation of the Multidimensional Fatigue Inventory in a US adult population sample. Popul. Health Metr. 2009, 7:18.
29. Lobnig B.M., Krömeke O., Optenhostert-Porst C., Wolf O.T. Hippocampal volume and cognitive performance in long-standing Type 1 diabetic patients without macrovascular complications. Diabet. Med. 2006, 23:32-39.
30. Lyoo I.K., Yoon S.J., Musen G., Simonson D.C., Weinger K., Bolo N., Ryan C.M., Kim J.E., Renshaw P.F., Jacobson A.M. Altered prefrontal glutamate-glutamine-gamma-aminobutyric acid levels and relation to low cognitive performance and depressive symptoms in type 1 diabetes mellitus. Arch. Gen. Psychiatry 2009, 66:878-887.
31. Manschot S.M., Brands A.M., van der Grond J., Kessels R.P., Alga A., Kappelle L.J., Biessels G.J. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 2006, 55:1106-1113.
32. Mavridis G., Souliou E., Diza E., Symeonidis G., Pastore F., Vassiliou A.M., Karamitsos D. Inflammatory cytokines in insulin-treated patients with type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 2008, 18:471-476.
33. Mogi N., Umegaki H., Hattori A., Maeda N., Miura H., Kuzuya M., Shimokata H., Ando F., Ito H., Iguchi A. Cognitive function in Japanese elderly with type 2 diabetes mellitus. J. Diabetes Complications 2004, 18:42-46.
34. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
35. Park C.R. Cognitive effects of insulin in the central nervous system. Neurosci. Biobehav. Rev. 2001, 25:311-323.
36. Petrova M., Prokopenko S., Pronina E., Mozheyko E. Diabetes type 2, hypertension and cognitive dysfunction in middle age women. J. Neurol. Sci. 2010, 299:39-41.
37. Reijmer Y.D., van den Berg E., Ruis C., Kappelle L.J., Biessels G.J. Cognitive dysfunction in patients with type 2 diabetes. Diabetes Metab. Res. Rev. 2010, 26:507-519.
38. Ribeiro-Filho F.F., Faria A.N., Azjen S., Zanella M.T., Ferreira S.R.G. Methods of estimation of visceral fat: advantages of ultrasonography. Obes. Res. 2003, 11:1488-1494.
39. Rigalleau V., Delafaye C., Baillet L., Vergnot V., Brunou P., Gatta B., Gin H. Composition of insulin-induced body weight gain in diabetic patients: a bio-impedance study. Diabetes Metab. 1999, 25:321-328.
40. Rijken P.M., Dekker J., Dekker E., Lankhorst G.J., Bakker K., Dooren J., Rauwerda J.A. Clinical and functional correlates of foot pain in diabetic patients. Disabil. Rehabil. 1998, 20:330-336.
41. Ruis C., Biessels G.J., Gorter K.J., van den Donk M., Kappelle L.J., Rutten G.E. Cognition in the early stage of type 2 diabetes. Diabetes Care 2009, 32:1261-1265.
42. Russell-Jones D., Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes. Metab. 2007, 9:799-812.
43. Sahakian B.J., Owen A.M. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J. R. Soc. Med. 1992, 85:399-402.
44. Sam S., Haffner S., Davidson M.H., D'Agostino R.B., Feinstein S., Kondos G., Perez A., Mazzone T. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care 2009, 32:932-937.
45. Sam S., Haffner S., Davidson M.H., D'Agostino R.B., Feinstein S., Kondos G., Perez A., Mazzone T. Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. Diabetes Care 2009, 32:1916-1920.
46. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Herqueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33.
47. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132:2169-2180.
48. Skeberdis V.A., Lan J., Zheng X., Zukin R.S., Bennett M.V.L. Insulin promotes rapid delivery of N-methyl-d-aspartate receptors to the cell surface by exocytosis. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:3561-3566.
49. Smets E.M., Garssen B., Bonke B., De Haes J.C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 1995, 39:315-325.
50. Strachan M.W., Reynolds R.M., Frier B.M., Mitchell R.J., Price J.F. The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies. Diabetes Obes. Metab. 2009, 11:407-414.
51. Van den Berg E., Reijmer Y.D., de Bresser J., Kessels R.P., Kappelle L.J., Biessels G.J. A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia 2010, 53:58-65.
52. Van Duinkerken E., Klein M., Schoonenboom N.S., Hoogma R.P., Moll A.C., Snoek F.J., Stam C.J., Diamant M. Functional brain connectivity and neurocognitive functioning in patients with long-standing type 1 diabetes with and without microvascular complications: a magnetoencephalography study. Diabetes 2009, 58:2335-2343.
53. Wan Q., Xiong Z.G., Man H.Y., Ackerley C.A., Braunton J., Lu W.Y., Becker L.E., MacDonald J.F., Wang Y.T. Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. Nature 1997, 388:686-690.
54. Weijman I., Ros W.J., Rutten G.E., Schaufeli W.B., Schabracq M.J., Winnubst J.A. Fatigue in employees with diabetes: its relation with work characteristics and diabetes related burden. Occup. Environ. Med. 2003, 60(Suppl. 1):93-98.
55. Weijman I., Ros W.J., Rutten G.E., Schaufeli W.B., Schabracq M.J., Winnubst J.A. Frequency and perceived burden of diabetes self-management activities in employees with insulin-treated diabetes: relationships with health outcomes. Diabetes Res. Clin. Pract. 2005, 68:56-64.
56. 2s γ-aminobutyric acid type A receptors. Neurosci. Lett. 2008, 443:27-31.
57. Winocur G., Greenwood C.E., Piroli G.G., Grillo C.A., Reznikov L.R., Reagan L.P., McEwen B.S. Memory impairment in obese Zucker rats: an investigation of cognitive function in an animal model of insulin resistance and obesity. Behav. Neurosci. 2005, 119:1389-1395.
58. World Health Organization, 2011. Diabetes: Fact sheet No. 312, August 2011. http://www.who.int/mediacentre/factsheets/fs312.
59. Yeung S.E., Fischer A.L., Dixon R.A. Exploring effects of type 2 diabetes on cognitive functioning in older adults. Neuropsychology 2009, 23:1-9.